American Diabetes Association Research Foundation and Novo Nordisk Award Grant to Study Intestinal Hormones

This press release is an announcement submitted by American Diabetes Association, and was not written by Diabetes Health.

The $1.2 million grant supports efforts to study the effects of intestinal hormones, such as glucagon-like peptide-1 (GLP-1), on obesity and pre-diabetes, two risk factors for type 2 diabetes and cardiovascular disease.

Sep 12, 2009

ALEXANDRIA, VA, Sep 01, 2009 (MARKETWIRE via COMTEX) - The American Diabetes Association Research Foundation has selected two scientists, University of Virginia Health System researcher Zhenqi Liu, MD, and Stanford University School of Medicine researcher Gerald Reaven, MD, to receive the American Diabetes Association-Novo Nordisk Clinical/Translational Research Award.

The $1.2 million grant supports efforts to study the effects of intestinal hormones, such as glucagon-like peptide-1 (GLP-1), on obesity and pre-diabetes, two risk factors for type 2 diabetes and cardiovascular disease. Each researcher will receive $600,000 to study the role of GLP-1 in people at risk for or with diabetes. GLP-1 is a hormone, secreted by L-cells located in the distal intestines, that stimulates insulin secretion in a glucose-dependent fashion.

Dr. Liu's research will help elucidate the role of native GLP-1 in the progression of obesity, pre-diabetes, and type 2 diabetes. The findings from this research could provide more insight into biomarkers that might be used to allow earlier intervention to prevent and/or treat obesity and/or pre-diabetes before type 2 diabetes develops.

Dr. Reaven's research will look beyond the direct effects of liraglutide, a GLP-1 analog, on glucose control, going on to explore areas such as weight control, satiety, and the effects on cardiovascular risk factors such as triglycerides and blood pressure.

"Studying the role of GLP-1 and other incretin hormones in people with type 2 diabetes and those at risk holds much promise," commented Scott Campbell, PhD, the American Diabetes Association Vice President of Research Programs. "Emerging science shows us that GLP-1 treatments can positively affect glucose metabolism and may increase beta cell mass, two important elements that could some day lead to a cure for type 2 diabetes."

"Novo Nordisk's highest priority has always been the health and well-being of people living with diabetes, and we strive to do everything we can to conduct and support research that will lead to the discovery of new, innovative treatments for people affected," said Nathaniel G. Clark, MD, MS, RD, Novo Nordisk's Senior Medical Advisor - Diabetes. "This is why, as part of our Changing Diabetes Leadership Initiative, we are truly pleased to support the American Diabetes Association in supporting studies investigating the full potential of this medication class in both those with and those at risk for type 2 diabetes."

Press Release

Click Here To View Or Post Comments

Categories: Diabetes, Diabetes, Insulin, Novo Nordisk, Pre-Diabetes, Research, Type 2 Issues


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.